Figure 1. Increasing μCi doses of 213Bi-CHX-A˝-Herceptin (213Bi-Herceptin) were administered intraperitoneally (i.p.) to mice bearing 3 d LS-174T i.p. xenografts. (Panel A: mock-treated; 250 μCi; 500 μCi; and 750 μCi 213Bi-Herceptin. 500 μCi 213Bi-HuIgG was used as a non-specific control.) Toxicity of radioimmunotherapy with 213Bi-Herceptin was determined by monitoring the animal weights for 2–3 weeks following radioimmunotherapy (RIT). The maximum relative weight reduction was calculated for each of the treatment groups and presented as box plots (Panel B). Specificity of the effect of the radioimmunotherapy is illustrated with a comparison between the mice that received either 500 μCi 213Bi-Herceptin or 500 μCi 213Bi-HuIgG (Panel C). The light line is the median. The upper region of the box represents the third quartile. The lower portion is the first quartile. The brackets delineate 1.5 times the interquartile range, and the lines outside of the brackets represent outlying observations.